Leftagraph

Every financial statement,
one clean chart.

Search any US-listed company. Data straight from SEC filings.

PROBuild your own list with the screener

Moderna, Inc. (MRNA) financial statements

Number look wrong? Tell us

Data table
PROBuild your own list with the screener

Moderna, Inc. (MRNA), most recent 12 months reported: revenue $2.23B, net loss $3.15B, free cash flow -$1.24B. Latest balance sheet on file: liquid cash $5.14B, total debt $591M, net cash $4.55B. From SEC filings. More on Moderna, Inc.: Revenue · Profitability · Cash flow · Debt Others in Biological Products, (No Diagnostic Substances): GILEAD SCIENCES, INC. · BIOGEN INC. · NEUROCRINE BIOSCIENCES INC · Exelixis Inc · QIAGEN N.V. · HALOZYME THERAPEUTICS, INC. · BIO-TECHNE Corp · BIOCRYST PHARMACEUTICALS, INC.

Stock screener

Watchlist